Thrivent Financial for Lutherans Acquires 5,440 Shares of Jazz Pharmaceuticals PLC $JAZZ

Thrivent Financial for Lutherans raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 38.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,720 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,440 shares during the period. Thrivent Financial for Lutherans’ holdings in Jazz Pharmaceuticals were worth $2,093,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JAZZ. SVB Wealth LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $36,000. Hantz Financial Services Inc. boosted its holdings in Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares in the last quarter. Geneos Wealth Management Inc. increased its position in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Acadian Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 1st quarter worth $90,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 53.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 902 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 313 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JAZZ. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday, November 17th. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. Bank of America increased their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. The Goldman Sachs Group lifted their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $200.47.

Insider Buying and Selling

In related news, Director Rick E. Winningham sold 5,500 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the sale, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This represents a 38.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 5,319 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $182.06, for a total transaction of $968,377.14. Following the completion of the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,276,604.72. This trade represents a 43.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 129,291 shares of company stock worth $22,745,410 over the last quarter. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Down 0.1%

JAZZ stock opened at $169.47 on Wednesday. The business has a 50 day moving average of $155.35 and a 200 day moving average of $132.30. The firm has a market cap of $10.30 billion, a PE ratio of -27.92, a price-to-earnings-growth ratio of 3.82 and a beta of 0.30. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.